{
  "source": "PA-Med-Nec-Simponi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2203-8\nProgram Prior Authorization/Medical Necessity\nMedication *Simponi® (golimumab)\n*This program applies to the subcutaneous formulation of golimumab.\nP&T Approval Date 5/2020, 5/2021, 6/2021, 12/2021, 5/2022, 5/2023, 7/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nSimponi (golimumab) is a tumor necrosis factor (TNF) blocker, indicated for the treatment of adult\npatients with moderately to severely active rheumatoid arthritis (RA) in combination with\nmethotrexate (MTX).1 Simponi, alone or in combination with methotrexate, is indicated for the\ntreatment of adult patients with active psoriatic arthritis (PsA).1 It is also indicated for the treatment of\nadult patients with active ankylosing spondylitis (AS).1 Simponi is also indicated in adult patients\nwith moderately to severely active ulcerative colitis who have demonstrated corticosteroid\ndependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral\ncorticosteroids, azathioprine, or 6-mercaptopurine. For ulcerative colitis, it is indicated for inducing\nand maintaining clinical response, improving endoscopic appearance of the mucosa during induction,\ninducing clinical remission, and achieving and sustaining clinical remission in induction responders.1\nAn intravenous formulation of golimumab, Simponi Aria®, is also available. Simponi Aria® is\nindicated for adult patients with moderately to severely active rheumatoid arthritis in combination\nwith methotrexate, active psoriatic arthritis in patients 2 years of age and older, adult patients with\nactive ankylosing spondylitis, and active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients\n2 years of age and older.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Simponi will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) One ",
    "heumatoid Arthritis (RA)\n1. Initial Authorization\na. Simponi will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of one non-biologic disease modifying anti-\nrheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine,\nhydroxychloroquine] at maximally indicated doses, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date, and\nduration of trial)b\n-OR-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of rheumatoid arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration of\ntherapy) [e.g., Cimzia (certolizumab), adalimumab, Olumiant (baricitinib),\nRinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Simponi therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Jannsen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Simponi*\n-AND-\n(3) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Jannsen sponsored ",
    "ting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Jannsen sponsored CarePath Savings program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Simponi will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n© 2024 UnitedHealthcare Services, Inc.\n2\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Simponi will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at maximally indicated dose,\nunless contraindicated or clinically significant adverse effects are experienced\n(document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims history\nor submission of medical records (Document drug, date, and duration of therapy)\n[e.g., Cimzia (certolizumab), adalimumab, Stelara (ustekinumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Rinvoq\n(upadacitinib)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Simponi therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Jannsen sponsor",
    "rds (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Jannsen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Simponi*\n-AND-\n(3) Patient is not receiving Simponi in combination with another immunomodulator\n[e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept), adalimumab,\nStelara (ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n© 2024 UnitedHealthcare Services, Inc.\n3\n(secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Jannsen sponsored CarePath Savings program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Simponi will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n(2) Patient is not receiving Simponi in combination with another immunomodulator\n[e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept), adalimumab,\nStelara (ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Simponi will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosi",
    "Authorization will be issued for 12 months.\nC. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Simponi will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or clinically\nsignificant adverse effects are experienced (document drug, date, and duration of\ntrials)\n© 2024 UnitedHealthcare Services, Inc.\n4\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of ankylosing spondylitis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration of\ntherapy) [e.g., Cimzia (certolizumab), adalimumab, Xeljanz/Xeljanz XR\n(tofacitinib), Rinvoq (upadacitinib)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Simponi therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Jannsen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Simponi*\n-AND-\n(3) Patient is not receiving Simponi in combination with with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Jannsen sponsored CarePath Savings program shall be required to meet initial authoriza",
    "eceipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Jannsen sponsored CarePath Savings program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Simponi will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n5\n(2) Patient is not receiving Simponi in combination with with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis (UC)\n1. Initial Authorization\na. Simponi will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) One of the following:\n(a) Patient has had prior or concurrent inadequate response to a therapeutic course of\noral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of ulcerative colitis as documented by claims history\nor submission of medical records (Document drug, date, and duration of therapy)\n[e.g., adalimumab, Stelara (ustekinumab), Xeljanz (tofacitinib), Rinvoq\n(upadacitinib)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Simponi therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Jannsen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of ",
    " of assistance from the Jannsen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a current\nuser of Simponi*\n-AND-\n(3) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n© 2024 UnitedHealthcare Services, Inc.\n6\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Jannsen sponsored CarePath Savings program shall be required to meet initial authorization\ncriteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Simponi will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim",
    " Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• The intravenous infusion is typically covered under the medical benefit. Please refer to the\nUnited Healthcare Drug Policy for Simponi Aria\n4. References:\n1. Simponi [package insert]. Horsham, PA: Janssen Biotech Inc.; September 2019.\n2. Simponi Aria [package insert]. Horsham, PA: Janssen Biotech, Inc.; February 2021.\n3. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for\nthe Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis Rheum.\n2016;68(1):1-26.\n© 2024 UnitedHealthcare Services, Inc.\n7\n4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis -- Section 6. Guidelines of care for the treatment of psoriasis and psoriatic\narthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol.\n2011;65:137-174.\n5. Yu D, van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and\nnonradiographic axial spondyloarthritis) in adults. Sieper, J (Ed). UpToDate. Accessed January\n14, 2019.\n6. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the\nmanagement of moderate to severe ulcerative colitis. Gastroenterology. 2020; 158(5):1450-61.\nProgram Prior Authorization/Medical Necessity - Simponi (golimumab)\nChange Control\n5/2020 New program\n5/2021 Annual review. Removed preceding month requirement from failure\ncriteria. Removed prescriber requirement from reauthorization criteria.\nRemoved drug documentation where only one drug is required.\nReferences and background updated.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD. Adde",
    "tion criteria.\nRemoved drug documentation where only one drug is required.\nReferences and background updated.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting previous or current therapy with a biologic\nDMARD in order to bypass step through non-biologic therapies if claim\nhistory not available.\n12/2021 Updated conventional DMARD bypass language for rheumatoid\narthritis, psoriatic arthritis and ulcerative colitis with no change to\nclinical intent. Updated initial authorization duration to 12 months for\nulcerative colitis. Updated CT/KY footnote.\n5/2022 Added targeted synthetic DMARD to bypass criteria for AS and added\nRinvoq and Xeljanz as a JAK inhibitor example where applicable.\nAdded Mississippi to state mandate language.\n5/2023 Annual review. Updated drug examples to mirror other pharmacy\nprograms.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no change to coverage criteria. Updated state\nmandate footnote.\n© 2024 UnitedHealthcare Services, Inc.\n8"
  ]
}